Literature DB >> 33443137

Immediate post-operative aneurysm occlusion after endovascular treatment of intracranial aneurysms with coiling or balloon-assisted coiling in a prospective multicenter cohort of 1189 patients: Analysis of Recanalization after Endovascular Treatment of intracranial Aneurysm (ARETA) Study.

Laurent Pierot1, Coralie Barbe2, Denis Herbreteau3, Jean-Yves Gauvrit4, Anne-Christine Januel5, Fouzi Bala6, Frédéric Ricolfi7, Hubert Desal8, Stéphane Velasco9, Mohamed Aggour10, Emmanuel Chabert11, Jacques Sedat12, Denis Trystram13, Gaultier Marnat14, Sophie Gallas15, Georges Rodesch16, Frédéric Clarençon17, Chrysanthi Papagiannaki18, Phil White19,20, Laurent Spelle21.   

Abstract

BACKGROUND: Coiling, including balloon-assisted coiling (BAC), is the first-line therapy for ruptured and unruptured aneurysms. Its efficacy can be clinically evaluated by bleeding/rebleeding rate after coiling, and anatomically evaluated by aneurysm occlusion post-procedure and during follow-up. We aimed to analyze immediate post-coiling aneurysm occlusion and associated factors within the Analysis of Recanalization after Endovascular Treatment of intracranial Aneurysm (ARETA) population.
METHODS: Between December 2013 and May 2015, 16 neurointerventional departments prospectively enrolled participants treated for ruptured and unruptured aneurysms (ClinicalTrials.gov: NCT01942512). Participant demographics, aneurysm characteristics, and endovascular techniques were recorded. In patients with aneurysms treated by coiling or BAC, immediate post-operative aneurysm occlusion was independently evaluated by a core lab using a 3-grade scale: complete occlusion, neck remnant, and aneurysm remnant.
RESULTS: Of 1135 participants (age 53.8±12.8 years, 754 women (66.4%)), 1189 aneurysms were analyzed. Treatment modality was standard coiling in 645/1189 aneurysms (54.2%) and BAC in 544/1189 (45.8%). Immediate post-operative aneurysm occlusion was complete occlusion in 57.8%, neck remnant in 34.4%, and aneurysm remnant in 7.8%. Adequate occlusion (complete occlusion or neck remnant) was significantly more frequent in aneurysms with size <10 mm (93.1% vs 86.3%; OR 1.8, 95% CI 1.1 to 3.2; p=0.02) and in aneurysms with a narrow neck (95.8% vs 89.6%; OR 2.5, 95% CI 1.5 to 4.1; p=0.0004). Patients aged <70 years had significantly more adequate occlusion (92.7% vs 87.2%; OR 1.9, 95% CI 1.1 to 3.4; p=0.04).
CONCLUSIONS: Immediately after aneurysm coiling, including BAC, adequate aneurysm occlusion was obtained in 92.2%. Age <70 years, aneurysm size <10 mm, and narrow neck were factors associated with adequate occlusion. TRIAL REGISTRATION NUMBER: NCT01942512, http://www.clinicaltrials.gov. © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  aneurysm; coil

Year:  2020        PMID: 33443137     DOI: 10.1136/neurintsurg-2020-017012

Source DB:  PubMed          Journal:  J Neurointerv Surg        ISSN: 1759-8478            Impact factor:   5.836


  4 in total

1.  Commentary: Automated Machine Learning Model Development for Intracranial Aneurysm Treatment Outcome Prediction: A Feasibility Study.

Authors:  Markus Huber; Markus M Luedi; Lukas Andereggen
Journal:  Front Neurol       Date:  2022-06-10       Impact factor: 4.086

Review 2.  Endovascular treatment for aneurysms at the A1 segment of the anterior cerebral artery: current difficulties and solutions.

Authors:  Kun Hou; Guichen Li; Yunbao Guo; Jinlu Yu
Journal:  Acta Neurol Belg       Date:  2020-10-27       Impact factor: 2.396

Review 3.  Treatment of unruptured middle cerebral artery aneurysms: Systematic review in an attempt to perform a network meta-analysis.

Authors:  Ignacio Arrese; Sergio García-García; Santiago Cepeda; Rosario Sarabia
Journal:  Front Surg       Date:  2022-09-28

4.  Aneurysm Rupture 5.5 Years after Woven EndoBridge device (WEB) Implantation.

Authors:  Elmar Spuentrup; Carolin Spüntrup; Fortesa Bytyqi; Christoph Kabbasch; Jan Walter
Journal:  Clin Neuroradiol       Date:  2021-03-09       Impact factor: 3.649

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.